Baseline patient and CAR T-cell therapy characteristics of all patients, according to timing of relapse/progression
| . | All (n = 238) . | D0-D30 (n = 54) . | D30-D90 (n = 102) . | >D90 (n = 82) . |
|---|---|---|---|---|
| Sex, male | 160 (67.2) | 37 (68.5) | 75 (73.5) | 48 (58.5) |
| Age ≥65 y | 91 (38.2) | 29 (53.7) | 37 (36.3) | 35 (42.6) |
| Histology | ||||
| DLBCL, NOS | 178 (74.8) | 36 (66.7) | 82 (80.4) | 60 (73.3) |
| PMBL | 11 (4.6) | 3 (5.6) | 2 (2.0) | 6 (7.3) |
| HGBCL | 3 (1.3) | 2 (3.7) | 1 (1.0) | 0 (0) |
| Transformed FL | 31 (13.0) | 7 (13.0) | 13 (12.7) | 11 (13.4) |
| Other∗ | 15 (6.3) | 6 (11.1) | 4 (3.9) | 5 (6.1) |
| >3 lines of prior therapy | 136 (57.1) | 40 (74.1) | 49 (48.0) | 47 (57.3) |
| Prior autologous transplant | 46 (19.3) | 9 (16.7) | 21 (20.6) | 16 (19.5) |
| ECOG PS at registration ≥2 | 28 (12.2) | 12 (23.1) | 13 (13.5) | 3 (3.7) |
| LDH prior to infusion > UNL | 72 (38.9) | 31 (67.4) | 27 (35.1) | 14 (22.6) |
| Bulky disease (>5 cm) | 53 (38.7) | 16 (51.6) | 24 (43.6) | 13 (25.5) |
| aaIPI 2-3 | 126 (57.0) | 8 (15.7) | 7 (7.6) | 1 (1.3) |
| Bridging therapy | 209 (87.8) | 49 (90.7) | 89 (87.2) | 71 (86.5) |
| Neutropenia prior to infusion (<1 G/L) | 31 (13.5) | 9 (18.8) | 13 (13.0) | 9 (11.1) |
| Lymphopenia prior to infusion (<1 G/L) | 168 (99.4) | 36 (100) | 73 (98.6) | 59 (100.0) |
| Ferritin prior to infusion > UNL | 133 (84.7) | 37 (88.1) | 57 (85.1) | 39 (81.3) |
| Median CRP prior to infusion, mg/L (range) | 20 (6-50) | 39 (0-349) | 18 (1-376) | 12.5 (0-204) |
| CAR T-cell product | ||||
| Tisagenlecleucel | 102 (42.9) | 33 (61.1) | 40 (39.2) | 29 (35.3) |
| Axicabtagene ciloleucel | 136 (57.1) | 21 (38.9) | 62 (60.7) | 53 (64.7) |
| . | All (n = 238) . | D0-D30 (n = 54) . | D30-D90 (n = 102) . | >D90 (n = 82) . |
|---|---|---|---|---|
| Sex, male | 160 (67.2) | 37 (68.5) | 75 (73.5) | 48 (58.5) |
| Age ≥65 y | 91 (38.2) | 29 (53.7) | 37 (36.3) | 35 (42.6) |
| Histology | ||||
| DLBCL, NOS | 178 (74.8) | 36 (66.7) | 82 (80.4) | 60 (73.3) |
| PMBL | 11 (4.6) | 3 (5.6) | 2 (2.0) | 6 (7.3) |
| HGBCL | 3 (1.3) | 2 (3.7) | 1 (1.0) | 0 (0) |
| Transformed FL | 31 (13.0) | 7 (13.0) | 13 (12.7) | 11 (13.4) |
| Other∗ | 15 (6.3) | 6 (11.1) | 4 (3.9) | 5 (6.1) |
| >3 lines of prior therapy | 136 (57.1) | 40 (74.1) | 49 (48.0) | 47 (57.3) |
| Prior autologous transplant | 46 (19.3) | 9 (16.7) | 21 (20.6) | 16 (19.5) |
| ECOG PS at registration ≥2 | 28 (12.2) | 12 (23.1) | 13 (13.5) | 3 (3.7) |
| LDH prior to infusion > UNL | 72 (38.9) | 31 (67.4) | 27 (35.1) | 14 (22.6) |
| Bulky disease (>5 cm) | 53 (38.7) | 16 (51.6) | 24 (43.6) | 13 (25.5) |
| aaIPI 2-3 | 126 (57.0) | 8 (15.7) | 7 (7.6) | 1 (1.3) |
| Bridging therapy | 209 (87.8) | 49 (90.7) | 89 (87.2) | 71 (86.5) |
| Neutropenia prior to infusion (<1 G/L) | 31 (13.5) | 9 (18.8) | 13 (13.0) | 9 (11.1) |
| Lymphopenia prior to infusion (<1 G/L) | 168 (99.4) | 36 (100) | 73 (98.6) | 59 (100.0) |
| Ferritin prior to infusion > UNL | 133 (84.7) | 37 (88.1) | 57 (85.1) | 39 (81.3) |
| Median CRP prior to infusion, mg/L (range) | 20 (6-50) | 39 (0-349) | 18 (1-376) | 12.5 (0-204) |
| CAR T-cell product | ||||
| Tisagenlecleucel | 102 (42.9) | 33 (61.1) | 40 (39.2) | 29 (35.3) |
| Axicabtagene ciloleucel | 136 (57.1) | 21 (38.9) | 62 (60.7) | 53 (64.7) |
Values are n (%), unless otherwise indicated.
aaIPI, age-adjusted International Prognostic Index; CRP, C-reactive protein; D, day; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; HGBCL, high grade B-cell lymphoma; LDH, lactate dehydrogenase; NOS, not otherwise specified; PMBL, primary mediastina B-cell lymphoma; UNL, upper normal limit.
3B-FL n = 2; primary central nervous system lymphoma n = 1; transformed marginal zone lymphoma n = 3; unclassifiable Hodgkin/DLBCL n = 9.